Growth arrest specific gene (GAS) 6 modulates platelet thrombus formation and vascular wall homeostasis and represents an attractive drug target

Current Pharmaceutical Design

Volumn 13, Issue 26, 2007, Pages 2656-2661

  Maree, Andrew O ^a   Jneid, Hani ^a   Palacios, Igor F ^a   Rosenfield, Kenneth ^a   MacRae, Calum A ^a   Fitzgerald, Desmond J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Early region 1A gene; Glycoprotein; Platelet response amplifier; Rreceptor tyrosine kinases; Vascular smooth muscle cells

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GROWTH ARREST SPECIFIC PROTEIN 6; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; PROTEIN INHIBITOR; PROTEIN KINASE ARK; PROTEIN KINASE NYK; PROTEIN KINASE SKY; PROTEIN S; PROTEIN TYROSINE KINASE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTICOAGULATION; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOT RETRACTION; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; DRUG TARGETING; ENDOTHELIUM CELL; FOAM CELL; HOMEOSTASIS; HUMAN; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STRUCTURE; REGULATORY MECHANISM; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HOMEOSTASIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PLATELET AGGREGATION; THROMBOSIS;

EID: 34548752391     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781662948     Document Type: Review

References (79)

1. Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell 1988; 54: 787-93.
2. Manfioletti G, Brancolini C, Avanzi G, Scheider C. The protein encoded by a growth arrest-specific gene (GAS6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993; 13: 4976-85.
3. Saccone S, Marcandalli P, Gostissa M, Schneider C, Della Valle G. Assignment of the human GAS6 gene to chromosome 13q34 by fluorescence in situ hybridization. Genomics 1995; 30: 129-31.
4. Munoz X, Sumoy L, Ramirez-Lorca R, Villar J, de Frutos PG, Sala N. Human vitamin K-dependent GAS6: Gene structure, allelic variation, and association with stroke. Hum Mutat 2004; 23: 506- 12.
5. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: Encyclopedia for gepes, proteins and diseases. Weizmann Institute of Science, Bioinformatics Unit and Genome Center (Rehovot, Israel), 1997. GeneCard for [GAS6] [Oct 15 2005] World Wide Web URL: http://bioinformatics.weizmann.ac.il/cards-bin/carddisp? [gene]. 2005.
6. Stauffer DR, Chukwumezie BN, Wilberding JA, Rosen ED, Castellino FJ. Characterization of transcriptional regulatory elements in the promoter region of the murine blood coagulation factor VII gene. J Biol Chem 1998; 273: 2277-87.
7. Hohenester E, Tisi D, Talts JF, Timpl R. The crystal structure of a laminin G-like module reveals the molecular basis of alpha-dystroglycan binding to laminins, perlecan, and agrin. Mol Cell 1999; 4: 783-92.
8. Sasaki T, Knyazev PG, Cheburkin Y, Gohring W, Tisi D, Ullrich A, et al. Crystal structure of a C-terminal fragment of growth arrest-specific protein GAS6. Receptor tyrosine kinase activation by laminin G-like domains. J Biol Chem 2002; 277: 44164-70.
9. Mark MR, Chen J, Hammonds RG, Sadick M, Godowsk PJ. Characterization of GAS6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem 1996; 271: 9785-9.
10. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996; 271: 30022-7.
11. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, et al. The anticoagulation factor protein S and its relative, GAS6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995; 80: 661-70.
12. Hubbard SR. Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 1999; 71: 343-58.
13. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-12.
14. Ohashi K, Nagata K, Toshima J, Nakano T, Arita H, Tsuda H, et al. Stimulation of sky receptor tyrosine kinase by the product of growth arrest-specific gene 6. J Biol Chem 1995; 270: 22681-4.
15. Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H, Hammonds RG. Reevaluation of the roles of protein S and GAS6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell 1995; 82: 355-8.
16. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995; 373: 623-6.
17. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, et al. Structural basis for GAS6-Axl signaling. EMBO J 2006; 25: 80-7
18. Angelillo-Scherrer A, Burnier L, Flores N, Savi P, DeMol M, Schaeffer P, et al. Role of GAS6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest 2005; 115: 237-46.
19. Graham DK, Bowman GW, Dawson TL, Stanford WL, Earp HS, Snodgrass HR. Cloning and developmental expression analysis of the murine c-mer tyrosine kinase. Oncogene 1995; 10: 2349-59.
20. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001; 293: 306-11.
21. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, et al. Deficiency or inhibition of GAS6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001; 7: 215-21.
22. Gould WR, Baxi SM, Schroeder R, Peng YW, Leadley RJ, Peterson JT, et al. GAS6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J Thromb Haemost 2005; 3: 733-41.
23. Bellosta P, Costa M, Lin DA, Basilico C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 1995; 15: 614-25.
24. Bellosta P, Zhang Q, Goff SP, Basilico C. Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene 1997; 15: 2387-97.
25. Fantl WJ, Johnson DE, Williams LT. Signaling by receptor tyrosine kinases. Annu Rev Biochem 1993; 62: 453-81.
26. Avanzi GC, Gallicchio M, Bottarel F, Gammaitoni L, Cavalloni G, Buonfiglio D, et al. GAS6 inhibits granulocyte adhesion to endothelial cells. Blood 1998; 91: 2334-40.
27. Avanzi GC, Gallicchio M, Cavalloni G, Gammaitoni L, Leone F, Rosina A, et al. GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. Exp Hematol 1997; 25: 1219-26.
28. Nakano T, Kawamoto K, Kishino J, Nomura K, Higashino K, Arita H. Requirement of gamma-carboxyglutamic acid residues for the biological activity of GAS6: Contribution of endogenous GAS6 to the proliferation of vascular smooth muscle cells. Biochem J 1997; 323 (Pt 2): 387-92.
29. Nakano T, Higashino K, Kikuchi N, Kishino J, Nomura K, Fujita H, et al. Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca(2+)-mobilizing growth factors. J Biol Chem 1995; 270: 5702-5.
30. McCloskey P. Fridell YW, Attar E, Villa J, Jin Y, Varnum B, et al. GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl. J Biol Chem 1997;272: 23285-91.
31. Yanagita M, Arai H, Nakano T, Ohashi K, Mizuno K, ? A, et al. GAS6 induces mesangial cell proliferation via latent transcription factor STAT3. J Biol Chem 2001; 276: 42364-9.
32. D'Arcangelo D, Gaetano C, Capogrossi MC. Acidification prevents endothelial cell apoptosis by Axl activation. Circ Res 2002; 91: E4-12.
33. Goruppi S, Ruaro E, Varnum B, Schneider C. GAS6-mediated survival in NIH3T3 cells activates stress signaling cascade and is independent of Ras. Oncogene 1999; 18: 4224-36.
34. O'Donnell K, Harkes IC, Dougherty L, Wicks IP. Expression of receptor tyrosine kinase Axl and its ligand GAS6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway. Am J Pathol 1999; 154: 1171-80.
35. Allen MP, Linseman DA, Udo H, Xu M, Schaack JB, Varnum B, et al. Novel mechanism for gonadotropin-releasing hormone neuronal migration involving GAS6/Ark signaling to p38 mitogen-activated protein kinase. Mol Cell Biol 2002; 22: 599-613.
36. Fridell YW, Villa J Jr, Attar EC, Liu ET. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem 1998; 273: 7123-6.
37. Lu Q, Gore M, Zhang Q, Camenisch T, Boast S, Casagranda F, et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 1999; 398: 723-8.
38. Ishimoto Y, Nakano T. Release of a product of growth arrest-specific gene 6 from rat platelets. FEBS Lett 2000; 466: 197-9.
39. Balogh I, Hafizi S, Stenhoff J, Hansson K, Dahlback B. Analysis of GAS6 in human platelets and plasma. Arterioscler Thromb Vasc Biol 2005; 25: 1280-6.
40. Clauser S, Bachelot-Lozat C, Fontana P, Gaussem P, Remones V, Aiach M, et al. Physiological plasma GAS6 levels do not influence platelet aggregation. Arterioscler Thromb Vasc Biol 2006; 26: E22.
41. Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost 2004; 92: 1175-81.
42. Moers A, Nieswandt B, Massberg S, Wettschureck N, Gruner S, Konrad I, et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med 2003; 9: 1418-22.
43. Ginsberg MH, Xiaoping D, O'Toole TE, Loftus JC, Plow EF. Platelet integrins. Thromb Haemost 1993; 70: 87-93.
44. Murao K, Imachi H, Sayo Y, Hosokawa H, Sato M, Ishida T, et al. A product of growth arrest-specific gene 6 modulates scavenger receptor expression in human vascular smooth muscle cells. FEBS Lett 1999; 459: 363-6.
45. Ross R. Genetically modified mice as models of transplant atherosclerosis. Nat Med 1996; 2: 527-8.
46. Geng YJ, Libby P. Progression of atheroma: A struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002; 22: 1370-80.
47. Yanagita M, Ishii K, Ozaki H, Arai H, Nakano T, Ohashi K, et al. Mechanism of inhibitory effect of warfarin on mesangial cell proliferation. J Am Soc Nephrol 1999; 10: 2503-9.
48. Hasanbasic I, Cuerquis J, Varnum B, Blostein MD. Intracellular signaling pathways involved in GAS6-Axl-mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 2004; 287: H1207-13.
49. Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, et al. Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 2005; 105: 1970-6.
50. Korshunov VA, Mohan AM, Georger MA, Berk BC. Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ Res 2006; 98: 1446-52.
51. Son BK, Kozaki K, Iijima K, Eto M, Kojima T, Ota H, et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring GAS6-Axl survival pathway. Circ Res 2006; 98: 1024-31.
52. Dormady SP, Zhang XM, Basch RS. Hematopoietic progenitor cells grow on 373 fibroblast monolayers that overexpress growth arrest-specific gene-6 (GAS6). Proc Natl Acad Sci USA 2000; 97: 12260-5.
53. Nakamura YS, Hakeda Y, Takakura N, Kameda T, Hamaguchi I, Miyamoto T, et al. Tyro 3 receptor tyrosine kinase and its ligand, GAS6, stimulate the function of osteoclasts. Stem Cells 1998; 16: 229-38.
54. Fiebeler A, Park JK, Muller DN, Lindschau C, Mengel M, Merkel S, et al. Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am J Kidney Dis 2004; 43: 286-95.
55. Yanagita M, Ishimoto Y, Arai H, Nagai K, Ito T, Nakano T, et al. Essential role of GAS6 for glomerular injury in nephrotoxic nephritis. J Clin Invest 2002; 110: 239-46.
56. Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, et al. GAS6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 2005; 68: 552-61.
57. Yin JL, Pilmore HL, Yan YQ, McCaughan GW, Bishop GA, Hambly BD, et al. Expression of growth arrest-specific gene 6 and its receptors in a rat model of chronic renal transplant rejection. Transplantation 2002; 73: 657-60.
58. Prieto AL, Weber JL, Tracy S, Heeb MJ, Lai C. GAS6, a ligand for the receptor protein-tyrosine kinase Tyro-3, is widely expressed in the central nervous system. Brain Res 1999; 816: 646-61.
59. Prieto AL, Weber JL, Lai C. Expression of the receptor protein-tyrosine kinases Tyro-3, Axl, and mer in the developing rat central nervous system. J Comp Neurol 2000; 425: 295-314.
60. Li R, Chen J, Hammonds G, Phillips H, Armanini M, Wood P, et al. Identification of GAS6 as a growth factor for human Schwann cells. J Neurosci 1996; 16: 2012-9.
61. Shankar SL, O'Guin K, Cammer M, McMorris FA, Stitt TN, Basch RS, et al. The growth arrest-specific gene product GAS6 promotes the survival of human oligodendrocytes via a phosphatidylinositol 3-kinase-dependent pathway. J Neurosci 2003; 23: 4208-18.
62. Lee WP, Liao Y, Robinson D, Kung HJ, Liu ET, Hung MC. Axl-GAS6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity. Mol Cell Biol 1999; 19: 8075-82.
63. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 2001; 37: 2264-74.
64. Sun W, Fujimoto J, Tamaya T. Coexpression of GAS6/Axl in human ovarian cancers. Oncology 2004; 66: 450-7.
65. Shain SA. Exogenous fibroblast growth factors maintain viability, promote proliferation, and suppress GADD45alpha and GAS6 transcript content of prostate cancer cells genetically modified to lack endogenous FGF-2. Mol Cancer Res 2004; 2: 653-61.
66. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
67. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
68. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
69. Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-5.
70. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46: 1258-63.
71. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153-8.
72. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women's Aealth Study: a randomized controlled trial. JAMA 2005; 294: 56-65.
73. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS. Aspirin and clopidogrel in acute coronary syndromes: Therapeutic insights from the CURE study. Arch Intern Med 2003; 163: 1145-53.
74. Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, et al. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J 2000; 21: 2042-55.
75. Maree A; Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: Where are we now? Semin Vasc Med 2003; 3: 385-90
76. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial Efficacy and safety of subcutaneous clioxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events. Am J Cardiol 1998; 82: 19L-24L.
77. Franke A, Kuhl HP. The role of antiplatelet agents in the management of patients receiving intracardiac closure devices. Curr Pharm Des 2006; 12(10): 1287-91.
78. Kanno Y, Matsuno H. The possibility of novel antiplatelet peptides: The physiological effects of low molecular weight HSPs on platelets. Curr Pharm Des 2006; 12(7): 887-92.
79. Matsuno H. Alpha2-antiplasmin on cardiovascular diseases. Curr Pharm Des 2006; 12(7): 841-7.